Kinoxis Therapeutics Pty Ltd

Kinoxis Therapeutics Pty Ltd is pleased to announce the successful completion of a Series B round of capital raise. A total of $14.5 million funding has been raised through this round, led by key investors Uniseed, UniSuper, University of Sydney, Stoic Venture Capital, Avicella Capital, as well as a number of sophisticated investors.   The funds raised will be used to support Phase 2 programs for Kinoxis’ lead drug candidate, KNX100, which addresses behavioural and psychological symptoms across multiple indications, including agitation and aggression in dementia and several substance use disorders.   One of the supported programs is CARES-X, a phase 2 clinical study commencing this month. First of its kind in Australia, CARES-X will be conducted across 8 sites with 60 patients, examining the safety, tolerability and efficacy of KNX100 when used as a treatment of agitation in dementia patients.   Agitation and aggression in dementia not only have a profound impact on caregivers, but also are often the driver for the transition to assisted living facilities, resulting in a significant economic burden to the public healthcare system. Commenting on the fundraise and the CARES-X study, Kinoxis CEO Hugh Alsop said:” “This injection of funding comes at an important time. We are targeting a significant unmet treatment need for dementia patients, potentially broadening the options for them to maintain a higher quality of life. This is a new and highly promising area of development for KNX100, and we are grateful to have had the strong support from our major investors.”   Thanks also to Lis Boyce at Piper Alderman and the team at Bio101 for their support through this round.   For more details on the Series B fund raise and the CARES-X study, read the full press release via this link: https://lnkd.in/gw9Htpem #AgitationinDementia #SubstanceUseDisorder #SeriesB #BiotechInvestment

Kinoxis Therapeutics Pty Ltd is pleased to share that our CEO, Hugh Alsop has been announced as the inaugural recipient of the CEO of the Year award at The Brooker Prize gala.   The CEO of the Year award recognises individuals who have made a significant commercial, educational, member-driven or research-based contribution to their organisation or the sector. Thank you Brooker Consulting for this prestigious acknowledgment of Hugh’s contribution to the biotech and life sciences industry. As seen in this photo: John Kurek, Investor Director at Uniseed and Dr Rachel C., Principal of Brooker Consulting with Kinoxis CEO, Hugh Alsop.   #leadershipaward #biotech #lifesciences

I recently attended the College on Problems of Drug Dependence (CPDD) Conference in lovely Montreal, Canada. With drug overdoses claiming a life every five minutes in the US alone, the work of the CPDD organization is more critical than ever. Key discussions at the conference included the importance of addressing polysubstance use and the urgent need for harm reduction strategies. Innovative therapies in development were also highlighted, along with a focused discussion on drug craving—a major factor in the cycle of substance use disorders and a key contributor to relapse. By effectively treating drug cravings, we could reduce the risk of relapse to drug taking. 👩🔬 At Kinoxis Therapeutics Pty Ltd, we are making significant strides in the field of substance use disorders. #CPDD2024 #DrugDependence #SubstanceUseDisorders #AddictionResearch #Montreal #Biotech

Great to see two of our University of Sydney start ups Kinoxis Therapeutics Pty Ltd (CEO, Hugh Alsop and Prof Michael Bowen) and Endo Axiom (Dr Nicholas Hunt) in the spotlight at #BIO2024. #LeadershipForGood

Kinoxis Therapeutics Pty Ltd CEO Hugh Alsop presenting at #BIO2024 on our clinical stage programs exploring KNX100 for treating agitation and aggression in dementia and substance use disorders

Excited to the share the Kinoxis Therapeutics story at the BIO International Convention in San Diego next week. Join me for my presentation on Wednesday, June 5 at 4:00 PM in Company Presentation Theater 4. See you there. #BIO2024 Kinoxis Therapeutics Pty Ltd

Kinoxis Therapeutics partners with the National Institute on Alcohol Abuse and Alcoholism (NIAAA) to evaluate lead compound, KNX100 for alcohol use disorder, under an executed Clinical Trial Agreement (CTA). Did you know that alcohol is one of the leading causes of preventable deaths, claiming 3 million lives worldwide every year? Globally, it is estimated that over 250 million individuals meet the criteria for alcohol use disorder. Despite this, current medications to treat the disorder are limited. Kinoxis’ lead candidate, KNX100, is being developed as a transdiagnostic treatment for substance use disorders. As part of the collaboration, the NIAAA will conduct an initial pharmacodynamic and pharmacokinetic interaction study of KNX100 and ethanol, as the first step to develop a safe and effective treatment for alcohol use disorder. This Phase 1 clinical trial will be conducted under a CTA between NIAAA and Kinoxis and is pending Institutional Review Board (IRB) approval and Investigational New Drug (IND) approval by the U.S. Food and Drug Administration. The collaboration between Kinoxis and the NIAAA marks a significant advancement in the progression of KNX100 for the treatment of alcohol use disorder. Read more about the partnership here: https://lnkd.in/gQmuVQu9 Learn more about Kinoxis Therapeutics here: https://lnkd.in/gAjjDEM4 #AlcoholUseDisorder #SubstanceUseDisorders #NovelTherapies #ClinicalTrial #Biotech #NIH #NIAAA #Biotechnology The National Institutes of Health

I really enjoyed participating in the session on Alcohol and opioids: overdose, stress, and treatment this morning at the International Drug & Alcohol Research Society Meeting in Rio, where I spoke about the Kinoxis Therapeutics Pty Ltd program developing the clinical stage KNX100 compound for the treatment of substance use disorders.

We're excited to announce the successful completion of KTX-101, a Phase 1 Study, investigating the safety, tolerability, and pharmacokinetics of KNX100 in healthy volunteers. This trial was a double-blind, randomized, placebo-controlled study, encompassing both single and multiple ascending doses and marks our first venture into human studies. KNX100 has shown to be safe and well-tolerated, paving the way for further exploration! Thank you to Nucleus Network and Alithia Life Sciences for their exceptional support and expertise in conducting our Phase 1 trial of KNX100. The close of our Phase 1 study marks a significant step in our journey to improve treatment outcomes for people suffering with debilitating psychiatric illnesses. Now, we’re gearing up for an ambitious Phase 2 program, exploring KNX100 for the treatment of Substance Use Disorders, including Opioid, Stimulant and Alcohol Use Disorder. #OpioidUseDisorder #StimulantUseDisorder #SubstanceUseDisorders #NovelTherapies #Biotech #ClinicalTrials 

As we observe National Drug and Alcohol Facts Week®, the stark reality of the toll associated with substance use disorders becomes even more clear. In 2023 alone, over 100,000 American lives were tragically lost to drug overdoses, with opioids being the culprit in over 80,000 of these cases. Equally alarming, is the fact that 29 million Americans are grappling with alcohol use disorder, each story unique yet part of a collective struggle that demands urgent action. At Kinoxis Therapeutics, we are developing innovative treatments for various substance use disorders. This includes our collaborative effort with NIH/NIDA, developing our novel small molecule, KNX100, in opioid use disorder. In addition to opioid use disorder, KNX100 has an extensive preclinical data package in animal models of methamphetamine, cocaine, nicotine, and alcohol use disorder. For more information about Kinoxis' program, visit our website. https://lnkd.in/gUudDqyf For more insights into National Drug and Alcohol Facts Week® visit NIDA's NDAFW page. https://lnkd.in/eYv79YgT #substanceusedisorder #addiction #drugawareness #opioidepidemic